Results 301 to 310 of about 2,386,530 (346)

Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

Expert Opinion on Biological Therapy, 2021
Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei   +2 more
openaire   +2 more sources

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

Expert Opinion on Biological Therapy, 2013
Multiple agents targeting the immune "checkpoint" programmed death-1 (PD-1) pathway have demonstrated early evidence of durable clinical activity and an encouraging safety profile in patients with various tumor types, including some cancers, such as non-small-cell lung cancer, historically perceived as non-immunogenic and thus nonresponsive to ...
Omid Hamid, Richard D Carvajal
exaly   +3 more sources

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Journal of Medicinal Chemistry, 2021
With the successful clinical application of anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) monoclonal antibodies (mAb), targeting the PD-1/PD-L1 interaction has become a promising method for the discovery of cancer therapy ...
Tianyu Wang, S. Cai, Mingming Wang, Wanheng Zhang, Kuojun Zhang, Dong Chen, Zheng Li, Sheng Jiang   +7 more
semanticscholar   +1 more source

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

European Journal of Cancer, 2018
Long-term responders have been observed with anti-programmed death 1 and anti-programmed death ligand 1 (anti-PD(L)1). Optimal duration of therapy in responding and stable disease (SD) patients is unclear with various attitudes encompassing treatment until progression disease, stopping therapy after a defined timeframe.We report the experience of 13 ...
A Bernard-Tessier, Antoine Hollebecque, Rastilav Bahleda   +2 more
exaly   +3 more sources

Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege

Transplantation, 2009
Immune responses are tempered in immunologically privileged sites including the testis. Previous studies have shown that islet transplantation in the testis significantly prolongs islet allograft survival. However, mechanisms underlying testicular immune privilege and intratesticular allograft survival remain unclear.Allogeneic murine islets were ...
Xuyang, Cheng, Hehua, Dai, Ni, Wan, Yolonda, Moore, Ramakrishna, Vankayalapati, Zhenhua, Dai   +5 more
openaire   +2 more sources

Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC

Hepatology, 2021
Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection.
Chenhe Yi, Lirong Chen, Zhifei Lin, Lu Liu, Wei-qing Shao, Rui Zhang, Jing Lin, Ju-bo Zhang, Wenwei Zhu, H. Jia, L. Qin, Lu Lu, Jinhong Chen   +12 more
semanticscholar   +1 more source

Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts

Journal of the American Academy of Dermatology, 2019
Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the ...
Wesley Y, Yu, Timothy G, Berger, Jeffrey P, North, Zoltan, Laszik, Jarish N, Cohen   +4 more
openaire   +2 more sources

Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.

Cancer Treatment Reviews, 2020
PURPOSE The combination of an anti-programmed death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) monoclonal antibody with platinum-based chemotherapy can improve outcomes for patients with advanced non-small-cell lung cancer (NSCLC) or small-cell ...
B. Hoffner, N. Leighl, M. Davies
semanticscholar   +1 more source

Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B

Hepatobiliary & Pancreatic Diseases International, 2013
The role of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) in persistent HBV infection is controversial. Increasing PD-1 and PD-L1 expression has been found in hepatitis B patients during immune clearance phase, but not in HBV-tolerant patients.
Wen-Jin, Zhang, Chuan-Hui, Peng, Shu-Sen, Zheng   +2 more
openaire   +2 more sources

Profiles of serum soluble programmed death‐1 and programmed death‐ligand 1 levels in chronic hepatitis B virus‐infected patients with different disease phases and after anti‐viral treatment

Alimentary Pharmacology and Therapeutics, 2020
Soluble programmed death‐1 (sPD‐1) and soluble programmed death‐ligand 1 (sPD‐L1) play a role in immune regulation of chronic hepatitis B virus (HBV) infection.
J. Xia, Rui Huang, Yuxin Chen, Yong Liu, Jian Wang, Xiaomin Yan, Zhaoping Zhang, Chao Wu   +7 more
semanticscholar   +1 more source